Back to mobile site

TD Cowen Reiterates Hold Rating on Myriad Genetics (MYGN)

November 4, 2024 9:24 AM EST Send to a Friend
TD Cowen analyst Dan Brennan reiterated a Hold rating and $30.00 price target on Myriad Genetics (NASDAQ: MYGN).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login